The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- EMCrit 266 – High Sensitivity Troponins with Louise Cullen - February 20, 2020
- EMCrit 265 – ECPR 2.0 (ECMO CPR) - February 5, 2020
- EMCrit – Midlines Part 2-Explosion with Rory Spiegel - February 1, 2020